文献速递神经肌肉病神经免疫

Gefurulimab治疗全身型重症肌无力的PREVAIL 3期随机临床试验

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

PREVAIL是一项3期双盲安慰剂对照试验,在20国113中心纳入260例AChR-Ab+全身型重症肌无力成人患者,评估每周一次皮下注射Gefurulimab的疗效与安全性。26周时MG-ADL与QMG评分改善均显著优于安慰剂,且起效早、持续至26周,不良事件发生率与安慰剂相似。

要点

  • Gefurulimab每周一次皮下自注,26周MG-ADL较基线变化显著优于安慰剂(-4.2 vs -2.6)。
  • QMG评分26周改善亦显著优于安慰剂(-4.5 vs -2.4),起效约4周并持续至26周。
  • 不良事件发生率与安慰剂相似,常见为注射部位反应、头痛、背痛和鼻咽炎,未见脑膜炎球菌感染。

核心结论

  • Gefurulimab在AChR-Ab+全身型重症肌无力中显示早期且持续的临床获益,耐受性良好,支持其作为每周一次自我给药的便捷治疗方案。

研究设计与样本

  • PREVAIL为3期双盲安慰剂对照试验,在20国113中心开展,2022年11月至2024年11月筛查随机,随机对照治疗期26周。
  • 共筛查405例,排除145例,随机260例(Gefurulimab 131例,安慰剂129例),249例完成26周治疗。
  • 纳入≥18岁AChR-Ab+全身型重症肌无力患者,MGFA分型II–IV,MG-ADL总分≥5。
  • 干预为每周一次皮下自我注射Gefurulimab或安慰剂。

主要发现

  • MG-ADL评分1周内改善,QMG评分4周内改善,并持续至26周。
  • 不良事件发生率组间相似,Gefurulimab常见治疗中出现的不良事件为注射部位反应、头痛、背痛和鼻咽炎。
  • 未报告脑膜炎球菌感染。

关键数值与推荐

  • 主要终点为26周MG-ADL总分较基线变化,关键次要终点为26周QMG总分较基线变化。
  • 所有主要和次要终点均达到统计学显著性。

临床怎么用

  • 对于AChR-Ab+全身型重症肌无力成人患者,Gefurulimab可作为每周一次皮下自注的便捷治疗选择,早期改善日常生活活动与定量肌无力评分。
  • 治疗期间需关注注射部位反应、头痛、背痛和鼻咽炎等不良事件,未报告脑膜炎球菌感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Gefurulimab is a novel dual-binding nanobody that blocks complement component 5 activation. Complement activation is a key pathogenic mechanism in anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG). OBJECTIVE: To evaluate the efficacy and safety of gefurulimab in adults with AChR-Ab+ gMG. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial, PREVAIL, was a phase 3, double-blind, placebo-controlled study conducted at 113 sites in 20 countries. Patients were screened and randomized from November 2022 to November 2024; the randomized controlled treatment period was 26 weeks. Participants were adults (aged ≥18 years) with AChR-Ab+ gMG, a Myasthenia Gravis Foundation of America classification II through IV, and a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of 5 or higher. INTERVENTION: Gefurulimab or placebo via once-weekly subcutaneous self-injection. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline in MG-ADL total score at week 26. The key secondary end point was change from baseline in Quantitative Myasthenia Gravis (QMG) total score at week 26. Safety was also assessed. RESULTS: Of 405 patients screened, 145 were excluded; 260 met eligibility criteria and were randomized (gefurulimab, n = 131; placebo, n = 129); 249 patients completed the 26-week randomized controlled treatment period. The mean (SD) age was 52.8 (15.73) years; 157 (60.4%) patients were female and 103 (39.6%) were male. All primary and secondary end points were met with statistical significance. Improvements occurred within 1 week for MG-ADL score and 4 weeks for QMG score and were sustained through week 26. Least-squares mean change from baseline at week 26 for MG-ADL and QMG total scores for gefurulimab vs placebo were -4.2 vs -2.6 (treatment difference, -1.6; 95% CI, -2.4 to -0.8; P < .001) and -4.5 vs -2.4 (treatment difference, -2.1; 95% CI, -3.1 to -1.1; P < .001), respectively. The incidence of adverse events (AEs) was similar between groups. Most common treatment-emergent AEs with gefurulimab were injection site reactions, headache, back pain, and nasopharyngitis. No meningococcal infections were reported. CONCLUSIONS AND RELEVANCE: Gefurulimab demonstrated both early and sustained clinical benefit in AChR-Ab+ gMG and was well tolerated, supporting its potential as a convenient, once-weekly, self-administered treatment regimen. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05556096.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Gwathmey KG, Saccà F, Howard JF, et al. Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42507440. doi:10.1001/jamaneurol.2026.2333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。